Efgartigimod PH20 SC in Bullous Pemphigoid (BALLAD+)

Phase 3, open-label trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest at 56 weeks and Number of Participants Who Discontinued Treatment Because of Safety Concerns at 56 weeks. Started Mar 2023; status: terminated.